Szwiec Marek, Tomiczek-Szwiec Joanna, Marciniak Wojciech, Derkacz Róża, Huzarski Tomasz, Cybulski Cezary, Gronwald Jacek, Osowiecka Karolina, Sibilski Robert, Narod Steven A, Lubiński Jan
Department of Surgery and Oncology, University of ZielonaGóra, Zyty 28, 65-046 Zielona Góra, Poland.
Department of Biology and Genetics, Faculty of Medicine, University of Opole, Oleska 48, 45-052 Opole, Poland.
Cancers (Basel). 2025 Feb 28;17(5):839. doi: 10.3390/cancers17050839.
Among patients treated with neoadjuvant chemotherapy (NAC), a high survival rate is observed for those who experience a pathological complete response (pCR). Various tumor factors are predictive of a pCR, but few host factors have been studied.We sought to inquire whether or not a patient's blood selenium level prior to treatment was predictive of a pCR.
We studied 329 women diagnosed with primary invasive breast cancer who were treated with neoadjuvant chemotherapy (NAC). We included patients with HER2-positive ( = 183) or triple-negative breast cancer ( = 146). Blood was collected before the initiation of treatment. Blood levels of selenium were quantified by mass spectroscopy. Each patient was assigned to one of three tertiles based on the distribution of blood selenium levels in the entire cohort. Patients with triple-negative breast cancer (TNBC) were treated with a range of combination chemotherapies. Patients with HER2-positive breast cancer received anti-HER2 treatment based on trastuzumab alone or trastuzumab and pertuzamab. After treatment, each patient was classified as having pCR or no pCR.
In the entire cohort, the pCR rate was 59.0% for women in the highest tertileof blood selenium (≥107.19 μg/L) compared to 39.0% for women in the lowest tertile (≤94.29 μg/L) ( = 0.003).
A high selenium level is predictive of pCR in women treated for HER2-positive or triple-negative breast cancer. If confirmed, this observation may lead to a study investigating if selenium supplementation improves pCR rates and survival in breast cancer women receiving NAC.
在接受新辅助化疗（NAC）的患者中，病理完全缓解（pCR）的患者生存率较高。多种肿瘤因素可预测pCR，但很少有宿主因素得到研究。我们试图探究治疗前患者的血硒水平是否可预测pCR。
我们研究了329例经新辅助化疗（NAC）治疗的原发性浸润性乳腺癌女性患者。其中包括HER2阳性（n = 183）或三阴性乳腺癌（n = 146）患者。在治疗开始前采集血液。通过质谱法定量血硒水平。根据整个队列中血硒水平的分布，将每位患者分配到三个三分位数之一。三阴性乳腺癌（TNBC）患者接受了一系列联合化疗。HER2阳性乳腺癌患者接受了基于曲妥珠单抗单药或曲妥珠单抗与帕妥珠单抗联合的抗HER2治疗。治疗后，将每位患者分类为有pCR或无pCR。
在整个队列中，血硒最高三分位数（≥107.19μg/L）的女性pCR率为59.0%，而血硒最低三分位数（≤94.29μg/L）的女性pCR率为39.0%（P = 0.003）。
高硒水平可预测接受HER2阳性或三阴性乳腺癌治疗的女性的pCR。如果得到证实，这一观察结果可能会促使开展一项研究，调查补充硒是否能提高接受NAC的乳腺癌女性的pCR率和生存率。
